Hollencrest Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Hollencrest Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.72K	Hold	80	–	–	﹤0.01%	953
2026 Q1	$4.13K	Hold	80	–	–	﹤0.01%	952
2025 Q4	$3.98K	Hold	80	–	–	﹤0.01%	938
2025 Q3	$3.82K	Hold	80	–	–	﹤0.01%	928
2025 Q2	$2.52K	Hold	80	–	–	﹤0.01%	940
2025 Q1	$2.62K	Hold	80	–	–	﹤0.01%	943
2024 Q4	$2.89K	Hold	80	–	–	﹤0.01%	976
2024 Q3	$2.49K	Hold	80	–	–	﹤0.01%	931
2024 Q2	$2.14K	Hold	80	–	–	﹤0.01%	921
2024 Q1	$2.73K	Hold	80	–	–	﹤0.01%	869
2023 Q4	$2.31K	Hold	80	–	–	﹤0.01%	876
2023 Q3	$2.21K	Hold	80	–	–	﹤0.01%	907
2023 Q2	$2.4K	Hold	80	–	–	﹤0.01%	943
2023 Q1	$2.9K	Hold	80	–	–	﹤0.01%	920
2022 Q4	$2.85K	Buy	+80	New	+$2.78K	﹤0.01%	903

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Hollencrest Capital Management's SUPN Position: Q2 2026 in Review

Hollencrest Capital Management held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 80 shares worth $3.72K. The position accounts for ﹤0.01% of the portfolio, ranked #953.

Hollencrest Capital Management first reported a position in SUPN in Q4 2022 and has held it in 15 quarters since. The position peaked at $4.13K in Q1 2026. 333 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Hollencrest Capital Management held 80 shares of Supernus Pharmaceuticals worth $3.72K as of Q2 2026.
Hollencrest Capital Management left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
Supernus Pharmaceuticals made up ﹤0.01% of Hollencrest Capital Management's portfolio in Q2 2026, its #953 holding.
Hollencrest Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
Hollencrest Capital Management's Supernus Pharmaceuticals position peaked at $4.13K in Q1 2026.
333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Hollencrest Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.